Anadrol and MENT Interaction: Synergistic | Peptide Database

Join others researching Ecdysterone — share findings, ask questions, and learn from real experiences Ecdysterone (20-Hydroxyecdysone) is a naturally occurring phytoecdysteroid -- a class of steroid hormones that regulate molting and metamorphosis in insects and crustaceans. Despite its name and steroidal structure, ecdysterone does not interact with the androgen receptor and operates through an entirely different mechanism than anabolic-androgenic steroids. It is found in meaningful concentrations in common foods such as spinach (Spinacia oleracea), quinoa (Chenopodium quinoa), and various other plants. Ecdysterone gained significant attention in the strength and performance community following a 2019 study from Freie Universitat Berlin, which demonstrated that trained individuals supplementing with ecdysterone experienced significantly greater muscle mass gains compared to placebo over a 10-week resistance training program. The effect sizes were large enough that the study authors themselves recommended the World Anti-Doping Agency (WADA) consider adding ecdysterone to the prohibited substances list. Unlike traditional anabolic agents, ecdysterone does not cause hormonal suppression, does not require post-cycle therapy, and carries an exceptionally mild side effect profile. Its mechanism appears to involve signaling through estrogen receptor beta (ERbeta), which activates anabolic pathways in skeletal muscle without the androgenic, estrogenic, or hepatotoxic effects associated with traditional performance-enhancing compounds. An injectable form has gained popularity among advanced users seeking higher bioavailability, as oral ecdysterone suffers from significant first-pass metabolism. Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling. ERbeta is expressed in skeletal muscle tissue, and its activation triggers downstream anabolic signaling cascades including the PI3K/Akt pathway, which promotes muscle protein synthesis and inhibits protein degradation. This pathway converges on mTOR (mechanistic target of rapamycin), a master regulator of muscle hypertrophy, leading to increased translation of muscle-specific proteins. Importantly, ecdysterone does not activate estrogen receptor alpha (ERalpha), which is responsible for the feminizing effects of estrogens, nor does it bind to the androgen receptor, glucocorticoid receptor, or mineralocorticoid receptor. This selectivity explains why ecdysterone does not produce the hormonal side effects associated with anabolic steroids -- there is no testosterone suppression, no testicular atrophy, no gynecomastia, no liver toxicity, and no virilization in women. Additional proposed mechanisms include enhanced nitrogen retention in muscle tissue, improved calcium handling in muscle fibers leading to better contractile efficiency, and mild anti-inflammatory effects that may support recovery from exercise-induced muscle damage. Some in vitro studies also suggest ecdysterone may increase satellite cell proliferation, which could contribute to long-term muscle growth capacity.

PE-22-28 shows rapid antidepressant effects in animal models (within 4 days), but it's currently research-only with no human clinical trials completed. It's not approved for therapeutic use. However, the preclinical evidence is strong enough that clinical development may follow if pharmaceutical companies invest in it.